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or locorregional treatment. All patients were treated with direct IMRT. Toxicity was analyzed using the scale of Harris and van
Limbergen and Common Terminology Criteria for Adverse Events (CTCAE) Versión 4.0.
Results. We have evaluated 301 patients with a mean age of 52 years and a median following time of 15 months (3–39). 97% of
the patients received a boost over the tumor bed (91.3% with brachytherapy). 77.4% were inﬁltrating tumors; 22.6% were DCIS.
When ﬁnishing the treatment, 75.8% of the patients suffered grade 1 radiodermatitis (fully recovered after a month in 94.1%)
and hyperpigmentation was grade 1 in 48.2% patients thirty days after treatment. Chronically, ﬁbrosis appeared in 50% of the
patients (48.2%: grade 1 and 1.8%: grade 2) and hyperpigmentation remained grade 1 in 30.9% of patients. No grade 3 or 4 toxicity
was reported. We found that ﬁnal aesthetic result in the evolution critically depends on the state of the breast after surgery and
before radiotherapy.
Conclusion. Hypofractionated treatment in breast cancer is safe in terms of toxicity (acute and chronic) and very well tolerated
with good cosmetic outcomes. It also provides patients the opportunity to reduce their visits to the hospital and return to their
daily lives. Another important issue is the cost savings when compared to conventional treatment.
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Objective. To evaluate the inﬂuence of radiation dermatitis in the quality of life ofwomenwith breast cancer treatedwith radiation
therapy after conservative surgery.
Material and methods. Observational, prospective longitudinal done at the Department of Radiation Oncology-CHGUV-ERESA
between December and June 2012 in 35 patients requiring breast irradiation. Inclusion criteria: Conservative surgery, absence of
cognitive impairment and Spanish-speaking. The assessment of quality of lifewas performed using two validated questionnaires
for Spanish, DLQI1 and Skindex-292-3. Three surveys were conducted DLQI (the ﬁrst and last week of treatment and one month
after the end). The Skindex-29 was performed at the end of treatment and at three scales are rated: functional, emotional and
symptomatic. All patients followed the protocol radiodermatitis prevention of service.
Results. In the valuation of impaired quality of life on the end of treatment shows that in DLQI: only 3 participants had scores of
10 or higher on a total score of 30, this represents a low inﬂuence. When spend a month of the end of treatment, further reduces
this inﬂuence. The items on pain, burning and itching were the highest. In Skindex-29 only two women had scores of 35 and 38
out of 100 representing a half affectation. In the remaining women, affectation was low or very low.
Conclusions. Contrary to what is concluded in recent publications,1–5 this study shows a low alteration of the quality of life of
womenwith breast irradiation. These results are highly dependent on Radiation Oncology servicewhere treatment takes place as
they depend protocols on the acceptance of treatment and the protocols for prevention and management of radiation dermatitis
that are used in each service.
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Introduction. Breast radiodermatitis not always appear uniformly distributed throughout the breast. Throughout the treatment,
it is common to see more afectation in some areas than in others.
